Menu Search
Equities

Ascentage Pharma Group International

ASPHF:PKC

Ascentage Pharma Group International

Actions
  • Price (USD)6.45
  • Today's Change0.00 / 0.00%
  • Shares traded50.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 14:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

  • Revenue in HKD (TTM)970.03m
  • Net income in HKD-387.02m
  • Incorporated2017
  • Employees574.00
  • Location
    Ascentage Pharma Group International68 Xinqing Road, Suzhou Industrial ParkSuzhou ChinaCHN
  • Websitehttps://www.ascentage.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.